Retatrutide FDA Approval Timeline Phase 3 trials conclude: May 2026 NDA submission: Late 2026 (projected) FDA decision window: Q1Q2 2027 Read the full Retatrutide FDA roadmap (20262028) Safety Update & New Side Effects (Dysesthesia) While Retatrutides results are unprecedented, Phase 3 data identified a new safety signal not commonly seen with other GLP-1 drugs
Macrophage M2 polarization induced by exosomes from adipose-derived stem cells contributes to the exosomal proangiogenic effect on mouse ischemic hindlimb
AOD-9604 works by stimulating lipolysis, the breakdown of fats and triglycerides, and inhibiting lipogenesis, the formation of new fat
However, side effects can be avoided by using a lower starting dose of Retatrutide
And so I asked him afterwards, explain the situation
Other studies demonstrated intravenous glutathione rapidly improved liver function, also evidenced by reduced biomarkers, in the treatment of other liver pathologies including chronic hepatitis B